Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG65WH)

• Drug Name: Ficlatuzumab Drug Info
• Synonyms: AV-299

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 2	[1]
Non-small-cell lung cancer	2C25.Y	Phase 2	[1]
Pancreatic cancer	2C10	Phase 2	[2]
Squamous cell carcinoma	2B60-2D01	Phase 2	[2]
Acute myeloid leukaemia	2A60	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMG65WH

Molecule-Related Drug Atlas

Drug(s) Targeting Hepatocyte growth factor (HGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VM-202	DMSW80U	Angina pectoris	BA40	Phase 3	[3]
Donaperminogene seltoplasmid	DMH8IT5	Diabetic foot ulcer	BD54	Phase 3	[4]
ANG-3777	DMGP8WX	Delayed graft function	4B24.0	Phase 3	[5]
Collategene	DM27H0P	Peripheral Ischemic Ulcers	BD41	Phase 2	[6]
MP0250	DMR3VCY	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[2]
ABI-011	DM1KD7U	Lymphoma	2A80-2A86	Phase 1	[2]
TAK-701	DML3M0O	Advanced malignancy	2A00-2F9Z	Phase 1	[7]
Rilotumumab	DMD8ZSW	Grade IV malignant glioma	2A00.0	Discontinued in Phase 2	[8]
N,O6-Disulfo-Glucosamine	DMYCV7U	Discovery agent	N.A.	Investigative	[9]
O2-Sulfo-Glucuronic Acid	DME78MS	Discovery agent	N.A.	Investigative	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatocyte growth factor (HGF)	TT4V2JM	HGF_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT02318368) A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
• [4] Clinical pipeline report, company report or official report of ViroMed.
• [5] Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. Kidney Int Rep. 2020 Sep 25;5(12):2325-2332.
• [6] Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010 Sep;17(9):1152-61.
• [7] Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103.
• [8] Clinical pipeline report, company report or official report of Amgen (2009).
• [9] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.